2017
DOI: 10.1590/1806-9282.63.07.566
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objective: To characterize the frequency of HER-2-positive breast cancer in Brazil. Method: In this prospective observational study, we first ascertained the HER-2 status of invasive breast cancer specimens by automated immunohistochemistry (IHC). For specimens classified as 2+ by IHC, we performed in situ hybridization (ISH). Results: From February, 2011 to December, 2012, 1,495 breast specimens were registered, and 1,310 samples collected at 24 centers were analyzed. Median patient age was 54 years, and the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
2
0
2

Year Published

2018
2018
2022
2022

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 25 publications
0
2
0
2
Order By: Relevance
“…Although most of studies have reported that patients with BC aged less than 50 years tend to have a higher expression of HER2 than those with 50 years or over, however, some studies have shown contradicting results. For example, Arias et al reported that, there was 57.7% and 41.1% of postmenopausal and premenopausal patients with BC that were expressing HER2 and the difference in expression of the biomarker was not statistically signi cant (p = 0.065) [37]. Mwakigonja et al reported that, the expression of HER2 in the patients with BC aged ≤ 55 years was 41% compared to 10% for those aged > 55 years and the difference was statistically signi cant (p = 0.079) [12].…”
Section: Discussionmentioning
confidence: 99%
“…Although most of studies have reported that patients with BC aged less than 50 years tend to have a higher expression of HER2 than those with 50 years or over, however, some studies have shown contradicting results. For example, Arias et al reported that, there was 57.7% and 41.1% of postmenopausal and premenopausal patients with BC that were expressing HER2 and the difference in expression of the biomarker was not statistically signi cant (p = 0.065) [37]. Mwakigonja et al reported that, the expression of HER2 in the patients with BC aged ≤ 55 years was 41% compared to 10% for those aged > 55 years and the difference was statistically signi cant (p = 0.079) [12].…”
Section: Discussionmentioning
confidence: 99%
“…Segundo o Inca, a incidência de câncer de mama no Brasil é de 56,33 casos a cada 100 mil mulheres (Inca, 2018). Entre essas pacientes, estima-se que 20% sejam HER-2 positivas (Arias et al, 2017). Quanto ao diagnóstico, 96% das pacientes são diagnosticadas em estágio I-III e 4% em estágio IV (Liedke et al, 2014).…”
Section: População Elegívelunclassified
“…Aproximadamente 20% dessas mulheres possuem o status HER-2 positivo, característica de tumores que está associada a maior agressividade da doença, maior taxa de recorrência e maior índice de mortalidade (Arias et al, 2017, Mitri et al, 2012. O trastuzumabe é um anticorpo monoclonal humanizado recombinante, desenvolvido por engenharia genética e que se liga seletivamente ao domínio extracelular da proteína do receptor-2 do fator de crescimento epidérmico humano (HER-2) (Hudis et al, 2007).…”
Section: Introductionunclassified
“…Overexpression of HER-2 receptors is a molecular classification that affects about 15 to 25% of the total number of breast cancer cases and is characterized by a poor prognosis and aggressive proliferation (Arias et al, 2017). It is the second most relevant target in the treatment of breast cancer, behind treatments aimed at estrogen receptors (Piccart et al, 2021).…”
Section: Introductionmentioning
confidence: 99%